Skip to content

Exercise and Prevention of Syncope: EXPOSE

EXercise for the Prevention of Syncope Evaluation

Status
Suspended
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00203593
Enrollment
20
Registered
2005-09-20
Start date
2006-03-31
Completion date
2007-06-30
Last updated
2007-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Syncope

Keywords

exercise, total peripheral resistance, venoconstriction, blood volume expansion, orthostatic tolerance

Brief summary

The purpose of this study is to determine whether eight weeks of exercise performed at an intensity of approximately 65% VO2max will improve symptoms associated with fainting (vasovagal syncope).

Detailed description

Background: Vasovagal syncope affects 20-30% of the population, and for those who faint recurrently it causes a significant reduction in the quality of life. Although significant progress has been made in the past 15 years in our understanding of its diagnosis and prognosis, our therapeutic attempts often end in failure. Many patients who have been diagnosed with vasovagal syncope have a reduced orthostatic tolerance. Improved orthostatic tolerance has been achieved through exercise in a number of studies on healthy individuals. However, its efficacy as a means of treatment for those with vasovagal syncope has not been thoroughly explored. Comparison: Subjects will be randomized to one of two groups: an exercise group or control. The exercise group will be asked to train at a target of approximately 65% of their maximum exercise capacity (VO2max) for 8 weeks/3 times per week. The control group will be asked to perform a series of neck rotation exercises. Orthostatic tolerance will be examined in both groups pre and post intervention.

Interventions

BEHAVIORALExercise
PROCEDUREVO2max test
BEHAVIORALHeart Rate
PROCEDUREBlood Pressure
BEHAVIORALTotal Peripheral Resistance

Sponsors

University of Calgary
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

a diagnosis of vasovagal syncope as the cause of loss of consciousness, \>1 lifetime syncope spell preceding enrolment, \>-3 points on the S3 score for structurally normal hearts, \>18 yrs of age with informed consent -

Exclusion criteria

subjects with a negative Physical Activity Readiness Questionnaire (PARQ), those who are unable to provide informed consent, those with a VO2max \>55ml/kg/min, those who exercise more than 30 minutes per day, 3 times per week, other causes of syncope, individuals with valvular, coronary, myocardial, or conductive abnormality, significant arrhythmia, hypertrophic cardiomyopathy, permanent pacemaker, seizure disorder, heart failure, major chronic cardiovascular disease, or renal dysfunction. \-

Design outcomes

Primary

MeasureTime frame
Orthostatic tolerance - this will be measured at baseline and post intervention

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026